Editorial standards
Peptide Research Journal publishes secondary summaries of the published record. A summary is a guide to a paper, a trial registry entry, or a public regulatory document. It is not a substitute for that source, and it is not a clinical recommendation.
What a summary has to do
Each article names the kind of evidence it is summarizing. A human trial is described as a human trial. An animal or cell study is described as preclinical and stays that way in the headline, the standfirst, and the body. A review of other papers is described as a review. A label, a compounding notice, or a registry record is described as a public document, not as a new experiment.
The standfirst states the population or model, the comparison, the main reported result, and the limit that matters. Numbers stay attached to the dose, the route, the duration, and the group in which they were measured. A mean change in one sample is not rewritten as a promise for a different dose, a shorter course, or a different group of people.
Primary sources
Every article links to the record a reader would need in order to check the summary. That record is a PubMed entry, a DOI, a ClinicalTrials.gov registration, or an agency document such as a prescribing label. The link is placed where the claim depends on it. If a paper, a registry entry, and a label all exist, the article says which sentence comes from which one.
The journal does not invent identifiers. If a DOI or a registry number cannot be confirmed, the article does not supply a lookalike. Titles are given so a reader can find the version of record. Publisher PDFs are not reproduced.
What the journal will not do
A summary does not convert an animal dose into a human regimen. It does not rank compounds for personal use. It does not close with a suggestion to buy a research chemical, and it does not treat a vendor’s catalog code as the name of a trial. Codes used in a supply listing are identified as catalog shorthand when they appear at all.
Discontinuation, adverse events, and secondary endpoints are taken from the paper’s own tables when the article discusses them. A social-media paraphrase is not a source for those figures. If the paper does not report a result, the summary does not fill the gap with a mechanism story and present it as an outcome.
Sections
The eight sections are categories of the same kind of post. Research news and recently published studies point at new or still-cited papers. Paper reviews are close readings written by the journal, not ratings left by visitors. Preclinical research is labeled as such. Emerging molecules covers mechanisms and early human work that is still moving. Commentary is the journal’s own argument about how to read the literature. Methods explains how to read a paper, a registry record, or a certificate. Industry and regulatory developments cover labels, compounding rules, and the distance between a trial result and an indication.
When the record changes
Approval status, compounding lists, and trial results change. The article says what the cited document said at the time it was read. If a label or a registry entry is later revised, the current agency or registry page is the authority, and the summary should be corrected when the change affects a number or a claim about status. The corrections page describes how that is done.
Commercial listings
A product page is not a study and not a certificate of a clinical result. The journal does not use a listing as evidence that a paper’s findings apply to a vial. On the rare occasion a listing is mentioned, the article says that the page is commercial paperwork, not a trial.